Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Heart Failure · Atrial Fibrillation · RYTM

Rhythm Pharmaceuticals Netherlands

Rhythm Pharmaceuticals Netherlands B.V.

Rhythm Pharmaceuticals Netherlands patent portfolio — 12 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
BRIGHTLANDS CHEMELOT CAMPUS, VAN ITERSON BUILDING, BURGEMEESTER LEMMENSSTRAAT 352, Geleen, nl HQ
2014 Founded
10 Employees
Public company Type
RYTM · NYSE Ticker
Company details
Status
Public
HQ
BRIGHTLANDS CHEMELOT CAMPUS, VAN ITERSON BUILDING, BURGEMEESTER LEMMENSSTRAAT 352, Geleen, nl
Founded
2014
Employees
10
Programs
73
Drugs
38
Patents
12
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Rhythm Pharmaceuticals Netherlands patents

12 pharmaceutical patents indexed for Rhythm Pharmaceuticals Netherlands. 0 expire within 24 months.

Rhythm Pharmaceuticals Netherlands has 12 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

12 patents

Patent portfolio

  1. US 12285460

    Pharmaceutical compositions

    Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12263202

    Method of treating melanocortin-4 receptor pathway-associated disorders

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12077612

    Peptide compositions

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11702448

    Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers

    Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11129869

    Pharmaceutical compositions

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10960046

    Method of treating melanocortin-4 receptor pathway-associated disorders

    Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10954268

    Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10858399

    Peptide compositions

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10196425

    Peptide compositions

    Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10167312

    Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers

    Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9845339

    Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers

    Expires Mon Dec 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9597302

    Combination of dofetilide and mexiletine for the prevention and treatment of atrial fibrillation

    Expires Mon Mar 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Rhythm Pharmaceuticals Netherlands have?

12 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Rhythm Pharmaceuticals Netherlands patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.